Obesity drug prices are dropping, but getting a steady supply remains a challenge

Wegovy and Zepbound Prices Fall, but Access to the Obesity Drugs Still Isn’t Guaranteed

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. “The medications should be available, the question is at what price and can people sustain that,” said Matt Maciejewski, a Duke University profes…

Company works to expand access to legitimate obesity solutions

JACKSON, Tenn. — Obesity medications, once facing shortages, are now widely available. You see advertisements for them online, especially on social media. While these medications are available, some patients still face challenges due to cost and insurance coverage. So how do consumers not get scammed into purchasing knockoff versions that may not be effective or safe? Living with obesity can have serious effects on the body, both physically and …

Editorial: Weight-loss drug turns public health opportunity into private luxury

The recent approval of weight-loss drug Wegovy in New Zealand has been hyped as a breakthrough in the country’s fight against obesity but instead highlights...

Novo Nordisk files high-dose Wegovy in EU

Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Prices fall, but access to obesity drugs isn’t guaranteed

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.